Vanda Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
54.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$262Mnext fiscal year
FY EPS (est.)
-$2.27next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Action Date for Imsidolimab BLA | 12 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Fanapt Net Product Sales Quarterly29.6M
HETLIOZ Net Product Sales Quarterly15.9M
PONVORY Net Product Sales Quarterly6.2M
Total Net Product Sales Quarterly51.7MTarget: 240000000 - 290000000
Watch Items
- FDA BLA Review for Imsidolimab in Generalized Pustular Psoriasis (GPP)Trigger: PDUFA target action date of December 12, 2026Action: Monitor FDA decision and prepare for potential commercial launch in the U.S.
- NEREUS (tradipitant) Commercial Launch and Direct-to-Consumer Platform PerformanceTrigger: Full-year 2026 NEREUS revenue guidance of $10 million to $30 millionAction: Track prescription volume, online ordering metrics, and direct home delivery efficiency via nereus.us.
- BYSANTI (milsaperidone) Commercial AvailabilityTrigger: Expected launch in the second half of 2026Action: Monitor market entry, physician adoption, and payer coverage for bipolar I disorder and schizophrenia.
- Phase III Clinical Trial of VQW-765 in Social Anxiety DisorderTrigger: Clinical study results expected by the end of 2026Action: Evaluate top-line efficacy and safety data to determine regulatory filing strategy.
Research as of 19 Jun 2026